NCT00052936

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating aggressive non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying how well giving cyclophosphamide, doxorubicin, vincristine, and prednisone together with or without rituximab works in treating older patients who have aggressive non-Hodgkin's lymphoma. (This trial is no longer randomized as of 6/2005).

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,506

participants targeted

Target at P75+ for phase_3 lymphoma

Timeline
Completed

Started Jan 2001

Typical duration for phase_3 lymphoma

Geographic Reach
2 countries

174 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2001

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

January 24, 2003

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 27, 2003

Completed
7.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 5, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 5, 2010

Completed
Last Updated

May 18, 2021

Status Verified

May 1, 2021

Enrollment Period

9.6 years

First QC Date

January 24, 2003

Last Update Submit

May 14, 2021

Conditions

Keywords

anaplastic large cell lymphomaangioimmunoblastic T-cell lymphomastage III grade 1 follicular lymphomastage III grade 3 follicular lymphomastage III grade 2 follicular lymphomastage I adult T-cell leukemia/lymphomastage II adult T-cell leukemia/lymphomastage III adult T-cell leukemia/lymphomastage IV adult T-cell leukemia/lymphomacontiguous stage II adult lymphoblastic lymphomanoncontiguous stage II adult lymphoblastic lymphomastage I adult lymphoblastic lymphomastage III adult lymphoblastic lymphomastage IV adult lymphoblastic lymphomacontiguous stage II adult diffuse large cell lymphomanoncontiguous stage II adult diffuse large cell lymphomastage I adult diffuse large cell lymphomastage III adult diffuse large cell lymphomastage IV adult diffuse large cell lymphomacontiguous stage II mantle cell lymphomanoncontiguous stage II mantle cell lymphomastage I mantle cell lymphomastage III mantle cell lymphomastage IV mantle cell lymphomacontiguous stage II adult Burkitt lymphomanoncontiguous stage II adult Burkitt lymphomastage I adult Burkitt lymphomastage III adult Burkitt lymphomastage IV adult Burkitt lymphomacontiguous stage II marginal zone lymphomanoncontiguous stage II marginal zone lymphomaextranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissuenodal marginal zone B-cell lymphomasplenic marginal zone lymphomastage I marginal zone lymphomastage III marginal zone lymphomastage IV marginal zone lymphoma

Outcome Measures

Primary Outcomes (1)

  • Time to treatment failure at 3 years within the study and then periodically after study completion

    3 years within the study and then periodically after study completion

Secondary Outcomes (5)

  • Complete response rate at 3 years within the study and then periodically after study completion

    3 years within the study and then periodically after

  • Progression rate

    3 years within the study and then periodically after

  • Survival

    3 years within the study and then periodically after

  • Tumor control

    3 years within the study and then periodically after

  • Disease-free survival

    3 years within the study and then periodically after

Study Arms (4)

S6

EXPERIMENTAL

6x CHOP-14

Biological: filgrastimDrug: CHOP regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapy

R6

EXPERIMENTAL

6x CHOP-14 + 8x Rituximab

Biological: filgrastimBiological: rituximabDrug: CHOP regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapy

S8

EXPERIMENTAL

8x CHOP-14

Biological: filgrastimDrug: CHOP regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapy

R8

EXPERIMENTAL

8x CHOP-14 + 8x Rituximab

Biological: filgrastimBiological: rituximabDrug: CHOP regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfateRadiation: radiation therapy

Interventions

filgrastimBIOLOGICAL
R6R8S6S8
rituximabBIOLOGICAL
R6R8
R6R8S6S8
R6R8S6S8
R6R8S6S8

36Gy on BULK and extranodal involvement

R6R8S6S8

Eligibility Criteria

Age61 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement) * CD20\^+ B-cell lymphoma or CD20\^- B-cell and T-cell lymphoma allowed * B-cell NHL including the following: * Stage III follicular lymphoma * Stage III follicular lymphoma and diffuse B-cell lymphoma * Lymphoblastic precursor B-cell lymphoma * Diffuse large cell B-cell lymphoma * Centroblastic * Immunoblastic * Plasmablastic * Anaplastic large cell * T-cell-rich B-cell lymphoma * Primary effusion lymphoma * Intravasal B-cell lymphoma * Primary mediastinal B-cell lymphoma * Mantle zone lymphoma, blastoid * Burkitt's lymphoma * Burkitt-like lymphoma * Aggressive marginal zone lymphoma (monocytoid) * T-cell NHL including the following: * Lymphoblastic precursor T-cell lymphoma * Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS) * Lennert's lymphoma * T-zone lymphoma * T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type * Anaplastic large cell lymphoma * ALK\^+ * ALK\^- * Extranodal NK/T-cell lymphoma, nasal type * Intestinal T/NK-cell lymphoma (with or without enteropathy) * Hepatosplenic gamma-delta lymphoma * Subcutaneous panniculitis-like PTCL * Aggressive T/NK PTCL * Anaplastic large-cell NHL, NOS * Bone marrow involvement no more than 25% * No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract PATIENT CHARACTERISTICS: Age * 61 to 80 Performance status * ECOG 0-2 OR * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * WBC at least 2,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 2 times upper limit of normal (ULN) * No active hepatitis infection Renal * Creatinine no greater than 2 times ULN Cardiovascular * No Canadian Cardiovascular Society class III or IV angina pectoris * No New York Heart Association class III or IV cardiac failure * Ejection fraction at least 50% * Fractional shortenings at least 25% by echocardiography or nuclear medicine examination Pulmonary * FEV1 at least 50% * Diffusion capacity at least 50% Other * No uncontrolled diabetes mellitus * No known hypersensitivity to any study medications * No other concurrent malignancy * HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy Surgery * Not specified Other * Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study) * No other concurrent lymphoma therapy * No concurrent participation in another treatment study

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (174)

Haematologisch Onkologische Praxis

Aachen, 52070, Germany

Location

Klinikum St. Marien

Amberg, D-92224, Germany

Location

Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

Ansbach, 91522, Germany

Location

II. Medizinische Klinik

Aschaffenburg, 63739, Germany

Location

Specialist Practice for Oncology

Aschaffenburg, 63739, Germany

Location

Haematologische Praxis

Augsburg, 86150, Germany

Location

Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg

Augsburg, 86150, Germany

Location

Klinikum Augsburg

Augsburg, D-86156, Germany

Location

Kreiskrankenhaus Aurich

Aurich, D-26603, Germany

Location

Regional Hospital Bad Hersfeld

Bad Hersfeld, 36251, Germany

Location

Humaine - Clinic

Bad Saarow, 15523, Germany

Location

Krankenhaus Hohe Warte Mediziniche Klinik

Bayreuth, D-95445, Germany

Location

Robert Roessle Comprehensive Cancer Center - Charite Campus Buch

Berlin, 13125, Germany

Location

Haematologisch-Onkologische Schwerpunktpraxis

Berlin, 13357, Germany

Location

Hospital Complex Bernburg

Bernburg, 06406, Germany

Location

Krankenhaus Bietigheim

Bietigheim, D-74321, Germany

Location

Saint Agnes Hospital

Bocholt, 46397, Germany

Location

Saint Josef Hospital

Bochum, 44791, Germany

Location

Knappschaft Krankenhaus

Bochum, D-44892, Germany

Location

Medizinische Poliklinik

Bonn, D-53111, Germany

Location

Rheinische Friedrich-Wilhelms-Universitat

Bonn, D-53113, Germany

Location

DIAKO Ev. Diakonie Krankenhaus gGmbH

Bremen, 28239, Germany

Location

Medizinische Klinik Am Lukas - Krankenhaus

Bünde, D-32257, Germany

Location

General Hospital

Celle, 29223, Germany

Location

Hospital Kuchwald Chemnitz

Chemnitz, 09113, Germany

Location

Praxis Fuer Haematologie Internistische Onkologie

Cologne, D-50677, Germany

Location

Medizinische Universitaetsklinik I at the University of Cologne

Cologne, D-50924, Germany

Location

Unknown Facility

Cologne-Kalk, D-51105, Germany

Location

Lung Clinic Cologne-Merheim

Cologne-Merheim, D-51109, Germany

Location

Carl - Thiem - Klinkum Cottbus

Cottbus, 03048, Germany

Location

Klinikum Darmstadt

Darmstadt, D-64283, Germany

Location

Saint Johannes Hospital Dortmund

Dortmund, 44137, Germany

Location

Universitatsklinikum Carl Gustav Carus

Dresden, D-01307, Germany

Location

St. Johannes Hospital - Medical Klinik II

Duisburg, 47166, Germany

Location

Franz Hospital Dulmen

Dülmen, 48249, Germany

Location

Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth

Düsseldorf, 40489, Germany

Location

Hans - Susemihl - Krankenhaus

Emden, 26721, Germany

Location

Klinikum Erfurt

Erfurt, D-99089, Germany

Location

St. Antonius Hospital

Eschweiler, 52249, Germany

Location

Universitaetsklinikum Essen

Essen, 45147, Germany

Location

Krankenhaus Nordwest

Frankfurt, D-60488, Germany

Location

Klinikum Frankfurt (Oder) GmbH

Frankfurt (Oder), D-15236, Germany

Location

Evang. Deaconess Hospital Freiburg

Freiburg im Breisgau, 79110, Germany

Location

Municipal Hospital Complex

Fulda, D-36043, Germany

Location

Robert - Koch Hospital

Gehrden, 30989, Germany

Location

Centre for Internal Medicine Gieben

Giessen, 35392, Germany

Location

Universitaetsklinikum Goettingen

Göttingen, 37075, Germany

Location

Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet

Greifswald, 17489, Germany

Location

Staedtisches Klinikum Guetersloh

Gütersloh, 33332, Germany

Location

Allgemeines Krankenhaus Hagen

Hagen, 58095, Germany

Location

St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH

Hagen, 58095, Germany

Location

Krankenhaus St. Elisabeth und St. Barbara

Halle, 06110, Germany

Location

Krankenhaus Martha-Maria Halle-Doelau gGmbH

Halle, 06120, Germany

Location

Universitaetsklinikum Halle

Halle, D-06120, Germany

Location

Unknown Facility

Hamburg, 20095, Germany

Location

University Medical Center Hamburg - Eppendorf

Hamburg, 20251, Germany

Location

Asklepios Klinik Nord Heidberg

Hamburg, 22413, Germany

Location

Allgemeines Krankenhaus Altona

Hamburg, 22763, Germany

Location

Haematologisch-Onkologische Praxis Altona

Hamburg, D-22767, Germany

Location

Evangelische Krankenhaus Hamm

Hamm, 59063, Germany

Location

Unknown Facility

Hanover, 30159, Germany

Location

Henriettenstiftung Krankenhaus

Hanover, 30559, Germany

Location

Krankenhaus Siloah - Medizinische Klinik II

Hanover, D-30449, Germany

Location

Medizinische Hochschule Hannover

Hanover, D-30625, Germany

Location

Oncology Specialists Clinic

Harrislee, D-24955, Germany

Location

Thoraxklinik Heidelberg

Heidelberg, 69126, Germany

Location

Medizinische Universitaetsklinik und Poliklinik

Heidelberg, D-69115, Germany

Location

Regional Hospital Heidenheim

Heidenheim, 89522, Germany

Location

Regional Hospital Am Plattenwald - Bad Friedrichshall

Heilbronn, 74177, Germany

Location

Klinikum Herford

Herford, D-32049, Germany

Location

Marienhospital at Ruhr University Bochum

Herne, D-44625, Germany

Location

Privatklinik Dr. R. Schindlbeck GmbH & Co. KG

Herrsching am Ammersee, D-82211, Germany

Location

Onkologische Schwerpunktpraxis

Hildesheim, D-31134, Germany

Location

Evang. Hospital

Holzminden, 37603, Germany

Location

Medical University Hospital Homburg

Homburg, D-66421, Germany

Location

Hospital Complex Hoyerswerda

Hoyerswerda, 02977, Germany

Location

Gemeinschaftspraxis Innere Medizin

Jena, D-07743, Germany

Location

Klinikum der Friedrich-Schiller Universitaet Jena

Jena, D-07747, Germany

Location

Municipal Hospital Complex of the University

Kaiserslautern, D-67655, Germany

Location

Staedtisches Klinikum Karlsruhe gGmbH

Karlsruhe, 76133, Germany

Location

Red Cross Hospital Kassel

Kassel, 34121, Germany

Location

Staedtisches Krankenhaus Kiel

Kiel, 23116, Germany

Location

Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH

Koblenz, 56068, Germany

Location

Praxis fuer Haematologie und Onkologie

Koblenz, D-56068, Germany

Location

Leonardis Clinic

Kornwestheim, D-70806, Germany

Location

Klinikum Krefeld GmbH

Krefeld, D-47805, Germany

Location

Frankenwald Klinik

Kronach, 96317, Germany

Location

Caritas - Krakenhaus Lebach

Lebach, 66822, Germany

Location

University Leipzig Clinic of Internal Medicine

Leipzig, 04103, Germany

Location

Klinikum "St. Georg" Leipzig

Leipzig, 04129, Germany

Location

Unknown Facility

Leipzig, D-04103, Germany

Location

Klinikum Lippe - Lemgo

Lemgo, D-32657, Germany

Location

St. Vincenz Hospital Limburg

Limburg, 65549, Germany

Location

St. Bonifatius Hospital Lingen

Lingen, 49808, Germany

Location

Dreifaltigkeits Hospital

Lippstadt, 59555, Germany

Location

Klinikum Ludwigsburg

Ludwigsburg, D-71640, Germany

Location

St. Marien Hospital Ludwighafen

Ludwigshafen, 67067, Germany

Location

Municipal Complex of Ludwigshafen

Ludwigshafen, D-67063, Germany

Location

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck

Lübeck, D-23538, Germany

Location

Staedtisches Klinikum Magdeburg - Altstadt

Magdeburg, 39104, Germany

Location

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg

Magdeburg, 39120, Germany

Location

Johannes Gutenberg University

Mainz, 55131, Germany

Location

III Medizinische Klinik Mannheim

Mannheim, D-68305, Germany

Location

Unknown Facility

Marburg, D-35037, Germany

Location

Universitaetsklinikum Giessen und Marburg GmbH - Marburg

Marburg, D-35043, Germany

Location

Regional Hospital Mayen

Mayen, 56727, Germany

Location

Klinikum Minden

Minden, D-32423, Germany

Location

Unknown Facility

Minden, D-32427, Germany

Location

Unknown Facility

Monchenglasbach/Rheydt, D-41239, Germany

Location

Ev. Hospital Bethesda

Mönchengladbach, 41061, Germany

Location

Hospital Maria-Hilf II

Mönchengladbach, 41063, Germany

Location

Munich Oncologic Practice at Elisenhof

Munich, D-80335, Germany

Location

Klinikum der Universitaet Muenchen - Innenstadt Campus

Munich, D-80336, Germany

Location

Krankenhaus Muenchen Schwabing

Munich, D-80804, Germany

Location

Klinikum der Universitaet Muenchen - Grosshadern Campus

Munich, D-81377, Germany

Location

Municipal Hospital Munich

Munich, D-81737, Germany

Location

Evangelisches Krankenhaus - Mulheim

Mülheim, 45466, Germany

Location

St. Marien Hospital - Muelheim an der Ruhr

Mülheim, 45468, Germany

Location

Kreiskrankenhaus Muenchberg

Münchberg, 95213, Germany

Location

Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster

Münster, D-48129, Germany

Location

Regional Hospital Neumarkt

Neumarkt, 92318, Germany

Location

Staedtisches Klinikum Neunkirchen gGmbH

Neunkirchen, 66538, Germany

Location

Lukaskrankenhaus Neuss

Neuss, D-41464, Germany

Location

Klinikum Nuernberg - Klinikum Nord

Nuremberg, D-90340, Germany

Location

Klinikum Offenburg

Offenburg, D-77654, Germany

Location

Hematologische Praxis

Oldenburg, 26121, Germany

Location

Ev. Hospital Oldenburg

Oldenburg, 26122, Germany

Location

Klinikum Oldenburg

Oldenburg, D-26133, Germany

Location

Paracelsus - Klinik Osnabrueck

Osnabrück, D-49076, Germany

Location

Municipal Hospital Complex

Pforzheim, D-75175, Germany

Location

Klinikum Ernst Von Bergmann

Potsdam, D-14467, Germany

Location

Kreiskrankenhaus Radebeul

Radebeul, D-01445, Germany

Location

Krankenhaus St. Elisabeth - Ravensburg

Ravensburg, 88212, Germany

Location

Klinikum der Universitaet Regensburg

Regensburg, 93042, Germany

Location

Hematologische Onkologische Praxis

Regensburg, 93047, Germany

Location

Krankenhaus Barmherzige Brueder Regensburg

Regensburg, D-93049, Germany

Location

Jakobi Krankenhaus

Rheine, 48431, Germany

Location

Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock

Rostock, 18057, Germany

Location

Klinik und Poliklinik fuer Strahlentherapie - Universitaetsklinikum Rostock

Rostock, 18059, Germany

Location

Unknown Facility

Rostock, D-18257, Germany

Location

Caritasklinik St. Theresia

Saarbrücken, 66113, Germany

Location

Schwerpunktpraxis fuer Haematologie und Onkologie

Saarbrücken, D-66113, Germany

Location

St. Elizabeth-Klinik Saarlouis

Saarlouis, 66713, Germany

Location

Martin - Luther Hospital

Schleswig, D-24837, Germany

Location

Deaconess Hospital

Schwäbisch Hall, 74523, Germany

Location

Leopoldina - Krankenhaus

Schweinfurt, D-97422, Germany

Location

Evang. Jung-Stilling Hospital

Siegen, 57074, Germany

Location

St. Lukas - Clinic Solingen

Solingen, 42697, Germany

Location

Klinik fuer Onkologie - Katharinenhospital Stuttgart

Stuttgart, 70174, Germany

Location

Diakonie Klinikum Stuttgart

Stuttgart, 70176, Germany

Location

Klinikum Stuttgart - Buergerhospital

Stuttgart, 70191, Germany

Location

Hospital Bad Cannstatt

Stuttgart, 70374, Germany

Location

Robert-Bosch-Krankenhaus

Stuttgart, 70376, Germany

Location

St. Elisabeth Hospital Thuine

Thuine, 49832, Germany

Location

Regional Hospital Traunstein

Traunstein, 83278, Germany

Location

Krankenanstalt Mutterhaus der Borromaerinnen

Trier, D-54290, Germany

Location

Unknown Facility

Trier, D-54290, Germany

Location

Krankenhaus Barmherzigen Brueder

Trier, D-54292, Germany

Location

Hospital Tutzing

Tutzing, 82327, Germany

Location

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm

Ulm, 89081, Germany

Location

Ev. Hospital Unna

Unna, 59403, Germany

Location

St. Marienhospital - Vechta

Vechta, 49377, Germany

Location

Municipal Hospital Complex

Villingen-Schwenningen, D-78045, Germany

Location

Regional Hospital Waldbrol

Waldbröl, 51545, Germany

Location

Evangelisches Krankenhaus Essen Werden

Werden, 45239, Germany

Location

Hospital Wetzler

Wetzlar, 35578, Germany

Location

Deutsche Klinik fuer Diagnostik

Wiesbaden, 65191, Germany

Location

Dr. Horst-Schmidt-Kliniken

Wiesbaden, 65199, Germany

Location

Ev. Hospital Witten-Herdecke

Witten, 58455, Germany

Location

Kliniken St. Antonius

Wuppertal, 42283, Germany

Location

University Wurzburg

Würzburg, 97070, Germany

Location

Municipal Hospital Complex Zwickau

Zwickau, D-08060, Germany

Location

City Hospital Triemli

Zurich, 8063, Switzerland

Location

UniversitaetsSpital Zuerich

Zurich, 8091, Switzerland

Location

Related Publications (8)

  • Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.

  • Christofyllakis K, Kaddu-Mulindwa D, Lesan V, Rixecker T, Kos IA, Held G, Regitz E, Pfreundschuh M, Bittenbring JT, Thurner L, Poeschel V, Ziepert M, Altmann B, Bewarder M. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma. Ann Hematol. 2024 Nov;103(11):4599-4606. doi: 10.1007/s00277-024-05973-9. Epub 2024 Sep 4.

  • Kuhnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017 Jul 1;28(7):1540-1546. doi: 10.1093/annonc/mdx128.

  • Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17.

  • Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014 Oct 10;32(29):3242-8. doi: 10.1200/JCO.2013.53.4537. Epub 2014 Aug 18.

  • Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3.

  • Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Moller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trumper L, Siebert R, Loeffler M, Rosenwald A, Ott G; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013 Mar 21;121(12):2253-63. doi: 10.1182/blood-2012-06-435842. Epub 2013 Jan 18.

  • Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15.

MeSH Terms

Conditions

LymphomaLymphoma, Large-Cell, AnaplasticImmunoblastic LymphadenopathyLymphoma, FollicularPrecursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellBurkitt LymphomaLymphoma, B-Cell, Marginal Zone

Interventions

FilgrastimRituximabVAP-cyclo protocolCyclophosphamideDoxorubicinPrednisoneVincristineRadiotherapy

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLymphoma, T-CellLymphoma, Non-HodgkinLymphadenopathyLeukemia, LymphoidLeukemiaHematologic DiseasesLymphoma, B-CellEpstein-Barr Virus InfectionsHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsTumor Virus Infections

Intervention Hierarchy (Ancestors)

Granulocyte Colony-Stimulating FactorColony-Stimulating FactorsGlycoproteinsGlycoconjugatesCarbohydratesHematopoietic Cell Growth FactorsCytokinesIntercellular Signaling Peptides and ProteinsPeptidesAmino Acids, Peptides, and ProteinsProteinsBiological FactorsAntibodies, Monoclonal, Murine-DerivedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsSerum GlobulinsGlobulinsPhosphoramide MustardsNitrogen Mustard CompoundsMustard CompoundsHydrocarbons, HalogenatedHydrocarbonsOrganic ChemicalsPhosphoramidesOrganophosphorus CompoundsDaunorubicinAnthracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicPolycyclic CompoundsAminoglycosidesGlycosidesPregnadienediolsPregnadienesPregnanesSteroidsFused-Ring CompoundsVinca AlkaloidsSecologanin Tryptamine AlkaloidsIndole AlkaloidsAlkaloidsHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingIndolizidinesIndolizinesTherapeutics

Study Officials

  • Michael G.M. Pfreundschuh, MD

    Universitaetsklinikum des Saarlandes

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 24, 2003

First Posted

January 27, 2003

Study Start

January 1, 2001

Primary Completion

August 5, 2010

Study Completion

August 5, 2010

Last Updated

May 18, 2021

Record last verified: 2021-05

Locations